These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26142341)

  • 1. Effect of Danlou Tablet () on peri-procedural myocardial injury among patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndrome: A study protocol of a multicenter, randomized, controlled trial.
    Wang L; Mao S; Qi JY; Ren Y; Guo XF; Chen KJ; Zhang MZ
    Chin J Integr Med; 2015 Sep; 21(9):662-6. PubMed ID: 26142341
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Wang L; Zhao X; Mao S; Liu S; Guo X; Guo L; Du T; Yang H; Zhao F; Wu K; Cong H; Wu Y; Yang PC; Chen K; Zhang M
    Evid Based Complement Alternat Med; 2016; 2016():7960503. PubMed ID: 27895696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Rationale for the Endothelin-1 Receptor Antagonism in the Prevention of Microvascular Injury in Patients with non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (ENDORA-PCI) Trial.
    Liou K; Jepson N; Buckley N; Chen V; Thomas S; Russell EA; Ooi SY
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):169-75. PubMed ID: 26814686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.
    Steg PG; Mehta S; Jolly S; Xavier D; Rupprecht HJ; Lopez-Sendon JL; Chrolavicius S; Rao SV; Granger CB; Pogue J; Laing S; Yusuf S
    Am Heart J; 2010 Dec; 160(6):1029-34, 1034.e1. PubMed ID: 21146654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.
    Liu T; Xie Y; Zhou YJ; Li YP; Ma HY; Guo YH; Liu YY; Zhao YX; Shi DM
    Chin Med J (Engl); 2009 Aug; 122(15):1732-7. PubMed ID: 19781316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Sodium Tanshinone IIA Sulfonate in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Controlled, Randomized Trial.
    Mao S; Wang L; Zhao X; Guo L; Lin Q; Wang X; Dai X; Shang H; Zhang M; Hinek A
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):321-329. PubMed ID: 32940893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of Chinese herbal medicines combined with conventional treatment in patients with acute coronary syndrome after percutaneous coronary intervention: A multicenter randomized controlled trial.
    Wang PL; Zhang L; Wang SL; Yang QN; Gao ZY; Du JP; Zhang DW; Fu CG; Gu F; Xu H; Li LZ; Wang CL; Shi DZ
    Chin J Integr Med; 2017 Oct; 23(10):740-746. PubMed ID: 27778264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nonculprit vessel myocardial perfusion on outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes: analysis from the ACUITY trial (Acute Catheterization and Urgent Intervention Triage Strategy).
    Lansky AJ; Ng VG; Meller S; Xu K; Fahy M; Feit F; Ohman EM; White HD; Mehran R; Bertrand ME; Desmet W; Hamon M; Stone GW
    JACC Cardiovasc Interv; 2014 Mar; 7(3):266-75. PubMed ID: 24650400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of myocardial blush grade after PCI in patients with NSTE-ACS: Analysis from the ACUITY trial.
    Ng VG; Lansky AJ; Toro S; Parise H; Cristea E; Mehran R; Stone GW
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):215-24. PubMed ID: 25641255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
    Lopes RD; de Barros E Silva PGM; de Andrade Jesuíno I; Santucci EV; Barbosa LM; Damiani LP; Nakagawa Santos RH; Laranjeira LN; Dall Orto FTC; Beraldo de Andrade P; de Castro Bienert IR; Alexander JH; Granger CB; Berwanger O
    JAMA Cardiol; 2018 Nov; 3(11):1113-1118. PubMed ID: 30264159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
    Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
    Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.
    Jang Y; Zhu J; Ge J; Kim YJ; Ji C; Lam W
    J Cardiol; 2014 May; 63(5):335-43. PubMed ID: 24216317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.
    Ge J; Kim YJ; Jang YS; Zhu J; Marschner IC; Lam W
    J Cardiol; 2010 May; 55(3):303-8. PubMed ID: 20350523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of angiography with a routine invasive strategy and long-term outcomes in non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II (Fragmin and Fast Revascularization During Instability in Coronary Artery Disease), ICTUS (Invasive Versus Conservative Treatment in Unstable Coronary Syndromes), and RITA-3 (Intervention Versus Conservative Treatment Strategy in Patients With Unstable Angina or Non-ST Elevation Myocardial Infarction) Trials.
    Damman P; van Geloven N; Wallentin L; Lagerqvist B; Fox KA; Clayton T; Pocock SJ; Hirsch A; Windhausen F; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2012 Feb; 5(2):191-9. PubMed ID: 22361604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early versus delayed percutaneous coronary intervention for patients with non-ST segment elevation acute coronary syndrome: a meta-analysis of randomized controlled clinical trials.
    Rajpurohit N; Garg N; Garg R; Choudhary A; Fresen J; Boren S; Dellsperger KC; Webel R; Aggarwal K; Alpert MA
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):223-31. PubMed ID: 22488783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
    Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
    J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Pre-Procedural Beta-Blocker on Clinical Outcome after Percutaneous Coronary Intervention in Acute Coronary Syndrome.
    Kim BS; Eom SY; Kim SH; Hwang HK; Park JS; Kim W; Lee JW; Rha SW; Kim GY; Lim SW; Lee SH; Chae JK; Woo SI; Bae JW; Kim HJ
    Int Heart J; 2019 Nov; 60(6):1284-1292. PubMed ID: 31735782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage.
    Marfella R; Rizzo MR; Siniscalchi M; Paolisso P; Barbieri M; Sardu C; Savinelli A; Angelico N; Del Gaudio S; Esposito N; Rambaldi PF; D'Onofrio N; Mansi L; Mauro C; Paolisso G; Balestrieri ML
    Int J Cardiol; 2013 Oct; 168(4):3954-62. PubMed ID: 23876463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).
    Patti G; Pasceri V; Mangiacapra F; Colonna G; Vizzi V; Ricottini E; Montinaro A; D'Ambrosio A; Wijns W; Barbato E; Di Sciascio G;
    Am J Cardiol; 2013 Jul; 112(2):162-8. PubMed ID: 23601577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy.
    Pride YB; Mohanavelu S; Zorkun C; Kunadian V; Giugliano RP; Newby LK; Braunwald E; Califf RM; Harrington RA; Gibson CM;
    JACC Cardiovasc Interv; 2012 Sep; 5(9):927-35. PubMed ID: 22995880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.